News | January 27, 2008

Arbor, Medtronic Close $20 Million Valve Licensing Agreement

January 28, 2008 - Arbor Surgical Technologies Inc. closed a $20 million dollar Series C financing round led by Medtronic Inc. as part of a licensing agreement, providing Medtronic with manufacturing, marketing and distribution rights to Arbor’s advanced trilobal pericardial valve technologies.

With the closing of this event, Arbor has raised approximately $54 million dollars to date. This financing event will allow Arbor to expand clinical trials of its core technologies, the Trilogy Aortic Valve System and the sutureless TRE implantation tool. These devices are designed to enable more surgeons to perform minimally invasive heart valve procedures.

Financial terms of the license agreement have not been disclosed. Arbor retains exclusive rights to the modular Trilogy Aortic Valve System and sutureless TRE implantation technologies.

For more information: www.arborsurgical.com


Related Content

News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
Subscribe Now